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Abstract In Alzheimer disease brain the microtubule associated
protein (MAP) d is abnormally hyperphosphorylated. The role of
protein phosphatases (PP) in the regulation of phosphorylation
of d was studied in undifferentiated SY5Y cells. In cells treated
with 10 nM okadaic acid (OA), a PP-2A/PP-1 inhibitor, the PP-
1 and -2A activities decreased by 60% and 100% respectively and
the activities of MAPKs, cdc2 kinase and cdk5, but not of GSK-
3, increased. OA increased the phosphorylation of d at Thr-231/
Ser-235 and Ser-396/404, but not at Ser-262/356 or Ser-199/202.
An increase in tyrosinated/detyrosinated tubulin ratio, a decrease
in the microtubule binding activities of d, MAP1b and MAP2,
and cell death were observed. Treatment with 1 Wm taxol
partially inhibited the cell death. These data suggest (1) that OA
induced hyperphosphorylation of d is probably the result of
activated MAPK and cdks in addition to decreased PP-2A and
PP-1 activities and (2) that in SY5Y cells the OA induced cell
death is associated with a decrease in stable microtubules.
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1. Introduction
Accumulation of paired helical ¢laments (PHFs) in selected
neurons is one of the histopathological hallmarks of the Alz-
heimer disease (AD) brain, and the microtubule associated
protein (MAP) d is the major protein subunit of PHF [1,2].
In the AD brain, d protein, the biological activity of which is
regulated by its degree of phosphorylation [3], is abnormally
hyperphosphorylated [4]. The AD hyperphosphorylated d
(ADP-d) contains 5^9 mol phosphate per protein molecule
as compared with 2^3 mol phosphate per mole normal d [5].
To date, 21 phosphorylated Ser/Thr sites have been identi¢ed
in PHF-d [6]. The ADP-d does not promote assembly of tu-
bulin into microtubules [7]; it sequesters normal d and high
molecular weight MAPs, MAP1 and MAP2, and causes dis-
assembly of microtubules in vitro [8]. The disruption of micro-
tubules and the consequent compromised axoplasmic trans-
port are believed to be responsible for the retrograde
degeneration in neurons with neuro¢brillary pathology in
AD brain [7,8]. Therefore, understanding of the processes
leading to hyperphosphorylation of d is important.
Several kinases and phosphatases are known to be involved
in the regulation of phosphorylation of d. The proline directed
kinases, i.e. mitogen activated protein kinases (MAPKs)
[9,10], cyclin dependent kinases (cdks) [10,11], and glycogen
synthase kinase-3 (GSK-3) [12], are thought to be active par-
ticipants in d phosphorylation in the brain since these kinases
can phosphorylate d in vitro at many of the sites characteristic
for AD.
To date, phosphorylation of only Ser and Thr and not of
Tyr has been observed in AD d. Among the Ser/Thr protein
phosphatases, PP-1, -2A and -2B have been shown to catalyze
dephosphorylation of the ADP-d [13,14]. Furthermore, the
activities of PP-1 and PP-2A towards phosphorylase kinase
(Phk) and the phosphatase activity towards the ADP-d are
compromised in AD brain [15,16].
Previously we reported that SH-SY5Y human neuroblasto-
ma cells, if grown in 5% fetal calf serum, contained d hyper-
phosphorylated at several of the same sites as in AD and it
had less ability to bind to microtubules [17]. Furthermore, d
hyperphosphorylation by treatment with okadaic acid (OA), a
PP-2A and PP-1 inhibitor, and its decrease in biological ac-
tivity had been reported in di¡erent cell lines [18]. However,
the protein kinase and protein phosphatase activities involved
in the phosphorylation of d in these cells were not known. In
the present study, phosphatase inhibitors were employed to
elucidate the role of protein phosphatases in the phosphory-
lation of d and the regulation of the microtubule system. We
found that in SY5Y cells OA inhibits the activities of PP-2A
and PP-1 and increases in an acute fashion the activities of
MAPK, cdc2 kinase and cdk5. These changes in phosphatase
and kinase activities alter the levels of phosphorylation of d.
Furthermore, OA and other PP-1 and -2A inhibitors produce
degeneration of SY5Y cells that is accompanied by a decrease
of detyrosinated tubulin (stable microtubules), and this degen-
eration is inhibited by taxol, a microtubule stabilizer.
2. Materials and methods
2.1. Reagents
OA, calyculin A, and tautomycin were purchased from Calbiochem
(San Diego, CA), deltamethrin from Alomone Labs (Jerusalem, Isra-
el) and taxol (paclitaxel) from Sigma (St. Louis, MO.). Cyclosporin A
was a gift from Sandoz (Tokyo, Japan).
2.2. Antibodies and recombinant d
The following site speci¢c phosphorylation dependent antibodies to
d, d-1 (d not phosphorylated at Ser-195, Ser-198, Ser-199, or Ser-202
[19]), PHF-1 (d phosphorylated at Ser-396, Ser-404 [20]), M4 (d phos-
phorylated at Thr-231, Ser-235 [21]), 12E8 (d phosphorylated at Ser-
262, Ser-356 [22]) and R145d (d phosphorylated at Ser-422) were
employed. Rabbit antiserum R145d was raised against the synthetic
peptide corresponding to residues 417^426 of d410, with Ser-422 phos-
phorylated. The peptide was conjugated to keyhole limpet hemocya-
nin and injected into two rabbits (400 Wg peptide at the initial immu-
nization and 200 Wg peptide for the booster injections in 3 weekly
intervals). Serum from one of the rabbits reacted strongly with neuro-
¢brillary tangles in AD hippocampus and on Western blots with
ADP-d but not with recombinant or normal brain d. Other primary
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antibodies employed were monoclonal antibodies YL 1/2 (anti-Tyr
tubulin, Sera Lab, Westbury NY), anti-Glu tubulin [23], 3G5 (anti-
MAP1B), HM2 (anti-MAP2A-C, Sigma), anti-MAP kinase antibody
and agarose conjugated anti-MAP kinase antibody (clone Z033,
Zymed, South San Francisco, CA), anti-cdc2 kinase antibody (sc-53,
Santa Cruz Biotechnology, Santa Cruz, CA), anti-cdk5 antibody (sc-
173, Santa Cruz). Antibodies sc-53 and sc-173 are highly speci¢c and
do not crossreact (information obtained from the supplier). The fol-
lowing rabbit antisera to synthetic peptides of PP-1, -2A and -2B [24]
and glycogen synthase kinase-3 [25] were employed: R129d (anti-PP-
1), R123d (anti-PP-2A), R126d (anti-PP-2B), R133d (anti-GSK-3).
Secondary antibodies employed were alkaline phosphatase conjugated
anti-mouse and anti-rabbit IgG antibodies (Sigma), 125I-conjugated
anti-mouse and anti-rabbit IgG antibodies (0.1 Wg/ml, Amersham,
Arlington Heights, IL), and £uorescein isothiocyanate (FITC) conju-
gated anti-mouse IgG antibodies (Cappel, Durham, NC). d410 (3-re-
peat d with two N-terminal inserts) was prepared as previously de-
scribed [26].
2.3. Cells, protein and viability assays
SH-SY5Y human neuroblastoma cells were obtained from Dr. June
L. Biedler (Sloan Kettering Institute, NY). Cells were cultured up to
about 70^80% con£uence in 100 mm or 60 mm diameter dishes at 5%
CO2 and 37‡C, employing D-MEM/F-12 medium (Gibco BRL, Gai-
thersburg, MD) supplemented with 5% fetal calf serum (FCS), 100
IU/ml of penicillin, and 100 Wg/ml of streptomycin. The medium was
changed every 3 days. For harvesting, the cells were ¢rst washed with
warm (37‡C) PBS to remove the loosely £oating dead or dying cells
and then collected by trituration. Cells were lysed on ice for 20 min in
lysis bu¡er (100 mM PIPES, pH 6.8, 0.1% Triton X-100, 2 mM
MgCl2, 1 mM EGTA, 0.1 mM EDTA, 25 mM NaF, 1 mM PMSF,
5 Wg/ml leupeptin, 5 Wg/ml aprotinin, 2 Wg/ml pepstatin A, 25 Wg/ml
phosphoramidon), and centrifuged at 200 000Ug for 30 min. The
supernatants, called ‘cell extracts’ in the following, were used for
Western blots, radioimmuno-dot-blot and microtubule binding assays.
The protein concentrations were assayed by the modi¢ed Lowry
method [27]. Live/Dead Eukolight Viability/Cytotoxicity kit (Molec-
ular Probes Inc., Eugene, OR) was employed to assay cytotoxicity.
2.4. Assay of site speci¢c d phosphorylation
Levels of phosphorylation of d at d-1 and PHF-1 sites were assayed
by radioimmuno-dot-blot as described previously [17,28]. Triplicate
samples (from three individual dishes) of cell extracts containing 1,
2, and 3 Wg of protein were applied to nitrocellulose membranes
(Schleicher and Schuell, Keene, NH) and dried at 37‡C. As a standard
for d-1 antibody 0.5, 1 and 2 ng of d410 was applied to the membranes.
d-1, with or without prior dephosphorylation of the protein on the
membrane with alkaline phosphatase (258 U/ml, 7^10 h, 37‡C, Boehr-
inger-Mannheim, Indianapolis, IL), and PHF-1 were employed as
primary antibodies and 125I-conjugated anti-mouse IgG as a secon-
dary antibody. The phosphorylation of d at M4, R145d and 12E8 sites
were assayed by Western blotting using 125I-conjugated anti-mouse
IgG as the secondary antibody.
All radioblots were scanned with a Fuji BAS 1500 Bio Image ana-
lyzer (Raytest USA Inc., Wilmington, DE). Images were processed
using the Tina software system and expressed as PSL (photo stimu-
latable luminescence units). From the di¡erent sample concentrations
for the dot blots used, curves were constructed and the slopes (PSL/Wg
protein) determined. Values for phosphorylation of the d-1 epitope
were determined by subtraction of the values of the untreated blot
from those of the alkaline phosphatase treated blot (total d). Changes
of phosphorylation at the PHF-1, M4 and 12E8 sites were calculated
from the di¡erences between the immunoreactivity levels of the un-
treated (100%) and the OA treated cells.
2.5. Protein phosphatase assays
Cells were lysed in lysis bu¡er containing no NaF and centrifuged
as above (see Section 2.3). For the PP-1 and -2A assays, 32P-labeled
phosphorylase was prepared as a substrate by phosphorylating phos-
phorylase b with Phk [15]. PP-1 and -2A activities were assayed in the
reaction mixture containing 20 mM Tris, pH 7.0, 0.1 mM EGTA,
15 mM L-mercaptoethanol, 5 WM ca¡eine, 0.2 mg/ml 32P-phosphoryl-
ase and 0.03 Wg/ml of cell extract protein in the absence or presence of
0.2 mg/ml of PP-1 inhibitor-I, respectively.
For PP-2B assay, Phk 32P-labeled catalytic subunit of cAMP de-
pendent kinase (Sigma) [15] was employed as a substrate. PP-2B ac-
tivity was assayed in the reaction mixture containing 50 mM Tris, pH
7.0, 10 mM L-mercaptoethanol, 4.0 WM 32P-Phk, and 0.025 Wg/ml of
cell extract protein in the presence or absence of 1 mM CaCl2 and 1
WM calmodulin. PP-2B activity was calculated by subtraction of phos-
phatase activity in the absence of CaCl2/calmodulin from the activity
in the presence of CaCl2/calmodulin.
2.6. Protein kinase assays
Activities of cdc2 kinase, cdk5 and MAPK were determined as
described previously [26] but in immunoprecipitates of these enzymes
isolated from the cell extracts with appropriate speci¢c antibodies. 2 Wg
of antibodies to cdc2 kinase or cdk5 together with immobilized pro-
tein G (Pierce, Rockford, IL) or 20 Wl of agarose conjugated antibody
to MAPK were mixed with 50 Wg of cell extract protein in 50 mM
Tris, pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 2 mM
EGTA, 1 mM PMSF, 5 Wg/ml leupeptin, 5 Wg/ml aprotinin, 2 Wg/ml
pepstatin and 25 Wg/ml phosphoramidon. After incubation at 4‡C
overnight the mixtures were centrifuged and precipitates were washed
three times. The precipitates were then dissolved in 50 mM Tris, pH
7.4, containing 10 mM MgCl2. Cdc2 protein kinase peptide substrate
(Promega, Madison, WI) was employed for the cdc2 kinase and cdk5
assays, and MAPK substrate peptide (UBI, Lake Placid, NY) was
employed for the MAPK assay. Precipitates were suspended in 20
Wl of bu¡er and incubated at 30‡C for 30 min in the reaction mixture
containing 30 mM Tris, pH 7.4, 10 mM MgCl2, 10 mM NaF, 1 mM
Na3VO4, 2 mM EGTA, 10 mM L-mercaptoethanol, and 200 WM
[Q-32P]ATP with each substrate.
For the GSK-3 assay, 20 Wl of cell extracts (diluted to 1 mg/ml) was
incubated at 30‡C for 30 min in the same reaction bu¡er as above
except that phosphoglycogen synthase peptide 2 (UBI, Lake Placid,
NY) was used as a substrate. GSK-3 activity was also determined by
immunoprecipitating the enzyme from 50 Wg of cell extracts with 2 Wl
of R133 antibody which recognizes both GSK-3 K and L [25]. Non-
speci¢c phosphorylation was subtracted from each total kinase activ-
ity.
2.7. Microtubule binding assay
MAPs binding to taxol stabilized microtubules was assayed as de-
scribed previously [17]. Brie£y, 900 Wg of cell extracts was mixed with
100 Wg of taxol polymerized microtubules (from MAPs free tubulin),
in lysis bu¡er without Triton X-100 but containing 20 WM taxol, and
incubated at 37‡C for 30 min. The microtubule bound proteins (pellet)
were separated from proteins not bound to microtubules (superna-
tant) by centrifugation at 70 000Ug for 30 min. The pellets were
suspended in the same volume as that of the supernatants and 1/10
of the volume analyzed on Western blots. d, MAP1b and MAP2 were
detected with antibodies d-1 (after dephosphorylation of the blot),
3G5 and HM2. Levels of bound and unbound MAPs were determined
with 125I-labeled secondary antibody. The radioactivities were scanned
and quanti¢ed and amounts of both microtubule bound and unbound
MAPs determined. The percentages of the bound MAPs were calcu-
lated from the amounts of total, i.e. bound and unbound, MAPs.
3. Results
3.1. E¡ect of protein phosphatase inhibitors on cell viability
OA is a speci¢c inhibitor towards PP-2A and PP-1. This
compound, though tumorigenic in most organs, causes degen-
eration of cells of neuronal origin [29]. To establish conditions
of phosphatase inhibition least cytotoxic to SY5Y cells, vari-
ous concentrations of the PP-1 and PP-2A inhibitors, OA
(Fig. 1a), calyculin A (Fig. 1b) and tautomycin (data not
shown) were tested for their cytotoxicity towards SY5Y cells.
The three inhibitors, though chemically di¡erent from one
another, were all cytotoxic. However, the toxicity was ob-
served at about 10^100 times the concentration of the in vitro
IC50 of each inhibitor. In contrast, the PP-2B inhibitors del-
tamethrin (Fig. 1c) and cyclosporin A (data not shown) did
not show any cytotoxic e¡ect even though the concentrations
employed were 100 times more than their IC50. Since 10 nM
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OA was the least cytotoxic of the three PP-1 and -2A inhib-
itors (even at 48 h 50% of the cells were viable), for further
studies this PP-2A/PP-1 inhibitor was used.
3.2. E¡ects of OA and cyclosporin A on the activities of PP-1,
PP-2A and PP-2B
To con¢rm the inhibitory e¡ect of OA and cyclosporin A
on PP-2A/-1 and PP-2B respectively, phosphatase activities
were assayed in cells treated with these inhibitors. In cells
treated with 10 nM OA the PP-2A activity decreased gradu-
ally starting from 1 h and was not detectable after 24 h,
whereas the PP-1 activity was only signi¢cantly decreased
(to 40%) after 12 h (Fig. 2a,b).
In contrast, no PP-2B activity was detected in untreated
SY5Y cells or cells treated with 10 WM cyclosporin A (data
not shown). Furthermore, on Western blots no PP-2B staining
was detected whereas in brain homogenate the 61 kDa band
of the catalytic subunit of PP-2B was clearly observed. In
contrast PP-1 and PP-2A were expressed in SY5Y cells (Fig.
2c).
3.3. Levels of site speci¢c d phosphorylation
The degree of phosphorylation of d at di¡erent sites was
assayed by radio-immuno blots. The d-1 site is already phos-
phorylated 70^80% in the untreated cells and the treatment of
the cells with 10 nM OA did not induce a signi¢cant increase
of phosphorylation (Fig. 3), whereas the phosphorylation of
the PHF-1 and R145d sites increased respectively up to two-
and ¢ve-fold of the control level at 24 h. In contrast, the
phosphorylation of d at the M4 site increased more than
two-fold between 30 min and 1 h after exposure of the cells
to OA and then decreased rapidly thereafter to the control
value. The phosphorylation at the 12E8 site was not changed
signi¢cantly in the OA treated cells. Unlike the d-1, R145d,
PHF-1 and M4 sites, the 12E8 site is canonical for a non-
proline dependent protein kinase.
3.4. Stimulation of proline directed protein kinase activities in
cells treated with OA
PP-2A has been hypothesized to play a role in several signal
transduction cascades. Western blots showed that cdc2, cdk5,
MAPK and GSK-3 K/L were expressed in SY5Y cells (data
not shown). These kinases have been previously shown in
vitro to phosphorylate d at the sites found in PHF-d [10^12].
Cdc2 kinase and cdk5 activities in control cells increased
two- to-four-fold at 30 min after medium change, and were
decreased to baseline at 1 h (Fig. 4). Addition of OA to the
medium resulted in a prolonged increase of cdk5 and cdc2
kinase activities reaching the maximum at 1 h and then a
return to about baseline between 3 and 6 h. An additional
peak of activity, especially in the case of cdk5, was observed
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Fig. 2. Activities of PP-1 and PP-2A in SY5Y cells treated with
10 nM OA. a,b: PP-1 and -2A activities were assayed using 32P-la-
beled phosphorylase as a substrate. PP-2A activities were deter-
mined in the presence of inhibitor-I. PP-1 activities were calculated
by subtraction of PP-2A activities from the total activities (without
inhibitor-I). Medium containing either 10 nM OA (F) or no OA (E)
was added at the 0 time point and protein phosphatase activities
were measured. Each data point represents the mean þ S.D. of three
di¡erent experiments. c: Expression of PP-2A, PP-1 and PP-2B in
SY5Y cells. The expression of PP-2A, PP-1 and PP-2B was studied
by Western blots: 50 Wg of 200 000Ug cell extract/lane was labeled
with anti-PP-1 (lane 1), anti-PP-2A (lane 2), and anti-PP-2B (lanes 3
and 4).
Fig. 1. Cytotoxic e¡ects of PP-1, PP-2A and PP-2B inhibitors and
their expression in SY5Y cells. SY5Y cells were treated with (a)
10 nM (W) and 100 nM (R) OA, (b) 1 nM (R) and 10 nM (W)
calyculin A, and (c) 1 WM deltamethrin and cells were counted in a
microscope using the live/dead assay. PP-1 and PP-2A inhibitors
(OA and calyculin A) were cytotoxic whereas PP-2B inhibitor (del-
tamethrin) was not. 100 nM and 1 WM tautomycin (PP-1 and PP-
2A inhibitor) also induced cytotoxicity whereas 1 WM and 10 WM
cyclosporin A (PP-2B inhibitor) did not (not shown).
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at 12 h. MAP kinase activity increased up to approximately
10-fold at 30 min after medium change in the control cells
whereas it increased to approximately 20-fold at 1 h in the OA
treated cells. In contrast, the GSK-3 activity was almost con-
stant in both control and OA treated cells.
All assays were performed employing speci¢c peptides as
substrates. To con¢rm the kinase activities towards d, the
kinases were ¢rst immunoprecipitated and then activities as-
sayed employing recombinant d as a substrate. Each of the
immunoprecipitated kinases had activity towards d. The in-
creases in the activities of cdc2, cdk5 and MAPK towards d in
the OA treated cells were not as large as those observed using
their respective substrate peptides (data not shown).
3.5. OA induces changes in tubulin and microtubule associated
proteins
In cells treated with OA, processes were retracted and the
cell bodies rounded up (data not shown). In order to inves-
tigate whether these obvious changes in cell morphology were
associated with the changes of cytoskeletal components, the
expression of tubulin and the binding to microtubules of
MAPs including MAP1b, MAP2 and d in the treated and
the untreated cells were analyzed. The carboxyl terminal of
tubulin is catalyzed by both carboxyl peptidase and tubulin-
tyrosine ligase resulting in detyrosinated tubulin (Glu-tubulin)
and tyrosinated tubulin (Tyr-tubulin) respectively [30]. The
Glu-tubulin is a marker of stable microtubules, and the Tyr-
tubulin is a marker of dynamic (rapid turnover) microtubules.
Western blots developed with speci¢c antibodies against both
Glu-tubulin and Tyr-tubulin revealed that in cells treated with
10 nM OA over a period of 48 h the levels of Glu-tubulin
decreased whereas the Tyr-tubulin levels increased (Fig. 5a).
To study whether the microtubule binding activities of
MAP1b, MAP2 and d might be a¡ected by the OA treatment,
the in vitro binding activity of the di¡erent MAPS to taxol
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Fig. 5. Changes in cytoskeletal protein in SY5Y cells treated with
OA. a: E¡ect of OA on Glu-tubulin. Western blots of cell extracts
(5 and 2 Wg) prepared from cells that had been exposed to OA for
di¡erent time periods were labeled with antibodies to Glu-tubulin
and Tyr-tubulin. Glu-tubulin, a marker for stable microtubules, was
decreased and Tyr-tubulin, a marker for rapid turnover microtu-
bules, was increased after OA treatment. b: Microtubule binding of
MAPs from the OA treated and control SY5Y cells. Cells were
treated with culture medium alone (C) or culture medium contain-
ing 10 nM OA (OA) for 24 h and cell extracts incubated with taxol
polymerized microtubules. The microtubules with bound MAPs (B)
were separated from the unbound MAPs (U) by centrifugation and
analyzed as described in Section 2 except that the blots were devel-
oped with the PAP reaction. *Treatment of the membranes with al-
kaline phosphatase prior to application of the antibody. Arrow-
heads indicate the position of MAP1B (left panel) and MAP2A, b
(middle panel).
Fig. 4. Activities of cdc2 kinase (a), cdk5 (b), MAPK (c) and GSK-
3 (d). 36 h before the start of the experiment the medium was
changed. At the starting point (‘0’) medium without inhibitor (E) or
medium plus 10 nM OA (R) was added. Cdc2, cdk5 and MAPK
activities were assayed after immunoprecipitation from cell extract
at di¡erent times; GSK-3 activity was assayed directly.
Fig. 3. Levels of site speci¢c phosphorylation of d in SY5Y cells.
The phosphorylation levels of d were assayed with ¢ve di¡erent
antibodies employing 125I conjugated anti-mouse IgG antibody as a
secondary antibody: (a) d-1; (b) PHF-1; (c) M4; (d) R145d; (e)
12E8. Phosphorylation levels were normalized by taking the starting
time (‘0’ points) as 100% except in the case of the d-1 site. d-1 anti-
body recognizes only non-phosphorylated epitope. Therefore, 100%
phosphorylation means no binding of this antibody to cell extracts
(theoretically complete phosphorylation). At ‘0’ point medium con-
taining 10 nM OA (R) or no OA (a) was added and phosphoryla-
tion levels of d were measured at di¡erent time periods.
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stabilized microtubules was determined. Western blots showed
that the microtubule binding of MAP1b and MAP2 was de-
creased (Fig. 5b and Table 1). Furthermore, MAP2 and more
so MAP1b were partially degraded in the OA treated cells. In
the case of MAP1b some of the fragmented protein was
bound to the microtubules. The binding activity of d which
was already strongly compromised because of hyperphospho-
rylation in the untreated SY5Y cells, was decreased further by
the OA treatment (Fig. 5b, Table 1).
3.6. The e¡ect of taxol on the OA induced cell death
Since the treatment of SY5Y cells with OA induced a de-
crease in the microtubule binding activity of the MAPs and a
decrease of the stable microtubules, the e¡ect of the micro-
tubule stabilizer taxol on the OA induced death of the cells
was investigated. The addition of taxol was found to cause a
signi¢cant reduction of the OA induced cell death after 12^48
h (Fig. 6).
4. Discussion
The abnormal hyperphosphorylation of d protein is thought
to be an important initial step to the neurodegeneration in
AD brain, because hyperphosphorylated d is not only incom-
petent in promoting microtubule assembly and binding to
microtubules but also disassembles microtubules and inhibits
their assembly by sequestering d, MAP1 and MAP2 [8,31].
However, the processes which lead to hyperphosphorylation
of d are still unclear. Proline dependent protein kinases cdc2,
cdk5, MAPK, and GSK-3 are known to phosphorylate d in
vitro at several of the same sites as the d in AD brain
[9,10,26], but increase in the activity of any of these kinases
in AD brain except in the case of cdc2 [32] has not yet been
demonstrated. On the other hand, the abnormally hyperphos-
phorylated d is readily dephosphorylated in vitro at several
sites by protein phosphatases PP-2A and PP-1 which restore
the normal biological activity of d [13,14,33] and the activities
of these phosphatases are compromised in AD brain [15,16].
In the present study, the inhibition of the PP-2A and PP-1
activities in SY5Y cells, which have minimal PP-2B activity,
produced hyperphosphorylation of d at speci¢c sites and up-
regulation of the activities of cdc2 kinase, cdk5 and MAPK
but not of GSK-3. These ¢ndings suggest that the inhibition
of PP-2A and PP-1 may lead to hyperphosphorylation and
decrease in microtubule binding of d not only by decrease in
dephosphorylation but also by increased phosphorylation ac-
tivity. Furthermore, the decrease in the OA induced cell death
by taxol, the decrease in the level of Glu-tubulin and the
degradation of MAP1b and MAP2 suggest that the inhibition
of PP-2A and PP-1 might cause the disruption of the cyto-
skeleton and degeneration of SY5Y cells not only by hyper-
phosphorylation of MAPs but possibly also by directly de-
creasing the number of the stable microtubules and
promoting the proteolysis of the HMW-MAPs. The stimula-
tion of activities of cdc2 kinase, cdk5 and MAPK for ex-
tended periods of time in the OA treated cells demonstrates
the involvement of PP-2A in signal transduction mechanisms
and suggests that in AD brain in which the PP-2A and PP-1
activity is impaired [15], cdk5 and MAPK might be involved
in the hyperphosphorylation of d.
OA, calyculin A and tautomycin are speci¢c inhibitors of
PP-2A and, at a lower potency, of PP-1. These inhibitors,
despite their chemically unrelated structure, all cause the
death of SY5Y cells. However, cytotoxicity is not seen in all
cell types. For example, in lymphoid tumor cells like a L-cell
lymphoma cell line and a T-cell leukemia line OA and caly-
culin A have been shown to prevent radiation, heat shock or
UV induced apoptosis [34]. The cell death observed in SY5Y
cells upon exposure to OA and the other phosphatase inhib-
itors might therefore be a direct consequence of the inhibition
of PP-2A and PP-1.
Upon OA treatment a signi¢cant decrease in PP-2A activity
was seen as early as after 1 h whereas distinct inhibition of
PP-1 was only measurable at 6^12 h. This delay is probably
due to the gradual di¡usion of the OA through the cell mem-
brane so that for PP-2A with an in vitro IC50 of 0.07 nM the
critical level of OA was reached much faster than for PP-1 for
which the IC50 is around 3.4 nM [35].
In the OA treated SY5Y cells, the phosphorylation level of
the PHF-1 and the R145d sites increased at 24 h and the
phosphorylation level of the M4 site increased at 1 h and
decreased until 24 h. In contrast, the phosphorylation levels
of the d-1 site and the 12E8 site remained relatively constant.
All these sites, except the 12E8 site, are canonical sites for
proline dependent kinases and are dephosphorylated by PP-
2A or PP-1 in vitro [13,14]. The exact cause of these di¡er-
ences remains unknown. The d-1 site is highly phosphorylated
(70^80%) in SY5Y cells and probably this site is easily ac-
cessed by active kinases. The plausible reason why complete
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Fig. 6. Inhibition of OA mediated cell death by taxol. SY5Y cells
were treated either with 10 nM (O) or 100 nM (a) OA alone (bro-
ken lines) or in the presence of 1 WM taxol (solid lines). After di¡er-
ent time periods the viability of the cells was determined as in Fig.
1. The cell death that had been induced by 10 nM or 100 nM OA
was signi¢cantly inhibited in the taxol treated cell cultures after
12 h.
Table 1
Binding of MAPs in SY5Y cell extracts to taxol stabilized microtu-
bules
MAPs % MAP bound
Control OA treated
d 9.0 þ 3.6 4.8 þ 1.8
MAP1b 81.1 þ 6.1 10.0 þ 1.6***
MAP2 76.2 þ 4.6 55.4 þ 4.1**
Cell extracts of SY5Y cells that had been either control treated (Con-
trol) or treated with 10 nM OA for 24 h (OA treated) were incubated
with taxol stabilized microtubules and the levels of MAPs bound to
the microtubules determined as described in Section 2.
**P6 0.005; ***P6 0.0005.
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phosphorylation of the d-1 site was not induced by the inhib-
ition of phosphatases is as follows. In SY5Y cells grown in 5%
fetal calf serum, non-phosphorylated d at the d-1 site is pre-
dominantly localized in the nucleus [17]. In the nucleus, this
site might be dephosphorylated by phosphatases that are not
sensitive to OA such as PP-4 and PP-5 that have been local-
ized in the nucleus [36]. However, the expression of these
phosphatases in SY5Y cells is not known.
The phosphorylation of the PHF-1 and 145d sites was in-
creased within 24 h whereas the phosphorylation of the M4
site rapidly increased and decreased back to the control level
within 3 h. The M4 site might be easily accessible to one or
more of the activated proline dependent kinases, followed by
its dephosphorylation by the remaining PP-1 activity. In con-
trast, the PHF-1 and R145d sites might not be favorable
substrates available to the activated kinases but the inhibition
of phosphatases, especially PP-2A, might have allowed the
increased phosphorylation level. Thus the rapid and slow
changes of phosphorylation might depend on the accessibil-
ities and/or kinetics of the phosphorylating and dephospho-
rylating enzymes for each site.
The di¡erential activation of various proline directed kin-
ases by OA observed in the present study is probably due to
di¡erent activation mechanisms. Inhibition of PP-2A may di-
rectly block the inactivation of MAPK [37] by not dephos-
phorylating it at Thr-183 whereas inhibition of PP-2A indi-
rectly activates cdc2 kinase through the upregulation of cdc25,
the activating dual speci¢c phosphatase for cdc2 [38].
The activation mechanism of cdk5 has not yet been dem-
onstrated. The present study is the ¢rst report in the cell
system which shows that like cdc2 kinase, cdk5 is activated
by serum containing medium (see Fig. 4b). Like with cdc2
kinase the total period of activated cdk5 was prolonged by
OA suggesting that cdk5 might also have a PP-2A sensitive
regulatory mechanism.
The activation of GSK-3 depends on the dephosphorylation
of Ser-9 (L isoforms) and Ser-21 (K isoforms), and PP-2A is
known to catalyze these sites [39]. Although PP-2A was fully
inhibited by 10 nM OA, no signi¢cant change of the GSK-3
activity was seen, probably because GSK-3 was dephospho-
rylated by another protein phosphatase(s).
The breakdown of microtubules which is caused by hyper-
phosphorylation, is believed to be one of the main causes of
neuronal death in AD brain. A previous study has shown that
OA treated ¢broblasts predominantly contain dynamic micro-
tubules by immuno£uorescence. [40]. In the present study we
found that Glu-tubulin was decreased and Tyr-tubulin was
increased in the OA treated SY5Y cells and the ability of d,
MAP1b and MAP2 from these cells to bind to microtubules
was decreased. The decreased binding of MAP1b and MAP2
to microtubules may be due to hyperphosphorylation and/or
their increased degradation. Generally in the process of cell
death or neurodegeneration components of the cytoskeleton
are degraded by activated proteases like cathepsin, calpain or
interleukin 1 converting enzyme [41]. Lysosomal abnormal-
ities have been indeed found in OA treated SY5Y cells [42].
OA has been reported to a¡ect the function of several other
proteins via the up-regulation of phosphorylation of, for ex-
ample, calcium channel protein [43], and a transcriptional
factor [44]. Thus, the degeneration of SY5Y cells by OA treat-
ment observed in the present study might be due to several
causes. However, one major factor is probably the breakdown
of the microtubule network due to the hyperphosphorylation
and degradation of the MAPs because the microtubule stabil-
izer taxol partly inhibited the cell death; co-treatment of the
SY5Y cells with OA and taxol does not cause dephosphoryl-
ation of d [Zhong et al., in preparation]. In addition to the
cytoskeletal function the microtubule network is critically im-
portant in the intracellular transport system [45]. A premature
activation of cdc2, i.e. activation of the kinase at an inappro-
priate time in the cell cycle, is believed to be a cause of apop-
tosis [46]. Furthermore, the activation of cdc2 has also been
reported to induce a catastrophe of the microtubule system
[47]. Thus, the increase in the activities of cdc2 and cdk5 in
the OA treated SY5Y cells observed in the present study
might be involved in the breakdown of the microtubule sys-
tem and consequently cell death.
In the AD brain due to the decreased activities of d phos-
phatases, processes similar to those in the OA treated SY5Y
cells might be triggered that lead to hyperphosphorylation of
d, the breakdown of the microtubule system in the a¡ected
cells and ¢nally cell death.
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